A strategy for increasing the efficiency of psychopharmacological treatment of hyperkinetic behavior disorder with pantogam

The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Search result: 0

Kupriianova T.A.

Moskovskiĭ nauchno-issledovatel'skiĭ institut psikhiatrii Roszdrava

Koren' E.V.

Moskovskiĭ NII psikhiatrii

Alabusheva N.N.

Moscow Research Institute of Psychiatry — the branch of FSBSI «Serbsky Federal Medical Research Center of Psychiatry and Narcology», Moscow, Russia

A strategy for increasing the efficiency of psychopharmacological treatment of hyperkinetic behavior disorder with pantogam

Authors:

Kupriianova T.A., Koren' E.V., Alabusheva N.N.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(11‑2): 75‑79

DOI: 10.17116/jnevro201711711275-79

Views: 773

Downloaded: 7

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Kupriianova TA, Koren' EV, Alabusheva NN. A strategy for increasing the efficiency of psychopharmacological treatment of hyperkinetic behavior disorder with pantogam. S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(11‑2):75‑79. (In Russ.)
https://doi.org/10.17116/jnevro201711711275-79

Подписка 2025-2 (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))

Close metadata

Objective. To assess short-term efficiency of hopantenic acid (pantogam) in the treatment of children with hyperkinetic behavior disorder, in whom the previous treatment with atomoxetine was not efficient. Material and methods. Twenty-four children (16 boys and 8 girls), aged 6—11 years, diagnosed with hyperkinetic behavior disorder (ICD-10 item F90.1) were enrolled in this open non-randomized study. Results and conclusion. A short-term positive therapeutic dynamics was observed when introducing hopantenic acid (pantogam) augmentation strategy to existing atomoxetine therapy. Qualitative improvements in children’s state were found not only in the ability to control symptoms but also in their social functioning levels and quality of life. The proposed therapeutic strategy can help to improve treatment outcomes for children with certain clinical forms of hyperkinetic behavior disorder.

Keywords:

children

hyperkinetic conduct disorder

pharmacotherapy

pantogam

atomoxetine

Authors:

Kupriianova T.A.

Moskovskiĭ nauchno-issledovatel'skiĭ institut psikhiatrii Roszdrava

Koren' E.V.

Moskovskiĭ NII psikhiatrii

Alabusheva N.N.

Moscow Research Institute of Psychiatry — the branch of FSBSI «Serbsky Federal Medical Research Center of Psychiatry and Narcology», Moscow, Russia

List of references:

Jensen CM, Steinhausen HC. Comorbid mental disorders in children and adolescents with attention-deficit/hyperactivity disorder in a large nationwide study. Atten Defic Hyperact Disord. 2015;7:1:27-38. https://doi.org/10.1007/s12402-014-0142-1
Koren EV, Kupriyanova TA. Classification in child psychiatry in the perspective of future icd-11. Sotsial’naya i klinicheskaya psikhiatriya. 2014;24:2:56-59. (In Russ.)
Pringsheim T, Hirsch L, Gardner D, Gorman D.A. The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysis. Part 1: psychostimulants, alpha-2 agonists, and atomoxetine. Can J Psychiatry. 2015;60:2:42-51.
Rader R, McCauley L, Callen EC. Current strategies in the diagnosis andtreatment of childhood attention-deficit/hyperactivity disorder. Am Fam Physician. 2009;79:8:657-665.
Kanbayashi Y. Hyperkinetic conduct disorder. Ryoikibetsu Shokogun Shirizu. 2003;40:10-12.
Kupriyanova TA, Koren EV. Pantogam augmentation in hyperkinetic behavior disorder treat ment. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2016;116:6:66-69. (In Russ.)
Kuhne M, Schachar R, Tannock R. Impact of comorbid oppositional or conduct problems on attention-deficit hyperactivity disorder. J of the Am Acad Child Adolesc Psychiatry. 1997;36:12:1715-1725. https://doi.org/10.1097/00004583-199712000-00020
Koren EV, Kovalyov AI. Classification perspectives in child psychiatry. Sotsial’naya i klinicheskaya psikhiatriya. 2011;21:1:37-42. (In Russ.)
Mezhdunarodnaya klassifikatsiya boleznei (10-i peresmotr). Klassifikatsiya psikhicheskikh i povedencheskikh rasstroistv. Klinicheskie opisaniya i ukazaniya po diagnostike. Per. na rus. Pod red. Nullera Yu.L., Tsirkina S.Yu. SPb.: Overlaid; 1994. (In Russ.)
Garg J, Arun P, Chavan BS. Comparative efficacy of methylphenidate and atomoxetine in oppositional defiant disorder comorbid with attention deficit hyperactivity disorder. Int J Appl Basic Med Res. 2015;5:2:114-118. https://doi.org/10.4103/2229-516x.157162
Hutchison SL, Ghuman JK, Ghuman HS, Karpov I, Schuster JM. Efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in patients with common comorbidities in children, adolescents and adults: a review. Ther Adv Psychopharmacol. 2016;6:5:317-334. https://doi.org/10.1177/2045125316647686
Bangs ME, Hazell P, Danckaerts M, Hoare P, Coghill DR, Wehmeier PM, Williams DW, Moore RJ, Levine L. Atomoxetine ADHD/ODD Study Group Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder. Pediatrics. 2008;121:2:314-320. https://doi.org/10.1542/peds.2006-1880
Newcorn JH, Spencer TJ, Biederman J, Milton DR, Michelson D. Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. J Am Acad Child Adolesc Psychiatry. 2005;44:3:240-248. https://doi.org/10.1097/00004583-200503000-00008
Biederman J, Spencer TJ, Newcorn JH, Gao H, Milton DN, Feldman PD, Witte MM. Effect of comorbid symptoms of oppositional defiant disorder on responses to atomoxetine in children with ADHD: a meta-analysis of controlled clinical trial data. Psychopharmacology (Berl). 2007;190:1:31-41. https://doi.org/10.1007/s00213-006-0565-2
Loy JH, Merry SN, Hetrick SE, Stasiak K. Atypical antipsychotics for disruptive behaviour disorders in children and youths. Cochrane Database Syst Rev. 2012;9:CD008559. https://doi.org/10.1002/14651858.cd008559.pub2
Pringsheim T, Hirsch L, Gardner D, Gorman DA. The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysis. Part 2: antipsychotics and traditional mood stabilizers. Can J Psychiatry. 2015;60:2:52-61.
Koren’ EV. Rasstroistva povedeniya. V sb.: Ratsional’naya farmakoterapiya v psikhiatricheskoi praktike. Rukovodstvo dlya praktikuyushchikh vrachei. Seriya «Ratsional’naya farmakoterapiya». Pod obshchei red. Aleksandrovskogo Yu.A., Neznanova N.G. M. 2014. (In Russ.)
Mozes T, Meiri G, Ben-Amity G, Sabbagh M, Weizman A. Reboxetine as an optional treatment for hyperkinetic conduct disorder: a prospective open-label trial. J Child Adolesc Psychopharmacol. 2005;15:2:259-269. https://doi.org/10.1089/cap.2005.15.259
Blader JC, Schooler NR, Jensen PS, Pliszka SR, Kafantaris V. Adjunctive divalproex versus placebo for children with ADHD and aggression refractory to stimulant monotherapy. Am J Psychiatry. 2009;166:12:1392-1401. https://doi.org/10.1176/appi.ajp.2009.09020233
Remschmidt H, Mattejat F. The quality of life of children and adolescents with ADHD undergoing outpatient psychiatric treatment: simple disorders of activity and attention and hyperkinetic conduct disorders in comparison with each other and with other diagnostic groups. Atten Defic Hyperact Disord. 2010;2:4:161-170. https://doi.org/10.1007/s12402-010-0036-9
Zavadenko NN, Suvorinova NYu. Attention-deficit hyperactivity disorder: determination of the optimal medical treatment duration. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2011;111:10:28-32. (In Russ.)
Sukhotina NK, Konovalova VV, Kryzhanovskaya IL, Kupriyanova TA. Efficacy of pantogam in the treatment of hyperkinetic disorders in children. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2010;110:12:24-28. (In Russ.)
Sukhotina NK, Egorova TI, Kibrik GN. Metodika provedeniya poliprofessional’nykh skriningovykh issledovanii rasprostranennosti giperkineticheskikh rasstroistv i narushenii povedeniya u detei. Metodicheskie rekomendatsii. M. 2009. (In Russ.)
Al’bitskii VYu, Baranov AA, Vinyarskaya IV. Izuchenie kachestva zhizni v pediatrii. Sotsial’naya pediatriya. 2010;10:20. (In Russ.)
Riley AW, Forrest CB, Starfield B, Rebok GW, Robertson JA, Green BF. The parent report form of the CHIP-child edition: reliability and validity. Med Care. 2004;42:210-220. https://doi.org/10.1097/01.mlr.0000114909.33878.ca
Zavadenko NN. Attention Deficit Hyperactivity Disorder: Modern Principles of Diagnostics and Treatment. Voprosy sovremennoi pediatrii. 2014;13:4:48-53. (In Russ.)

Close metadata

Log in to the site using your account in one of the services

Registration

Last Name

Name

Middle Name

E-mail

Phone

Address

Country

Zip

City

Region

Street

Home

Apartmen

Legal entity name

ИНН

КПП

Password

Password

Repeat password

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.